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Abstract 
 
Context: Prostate biopsy (PB) represents the gold standard method to confirm the presence of 
cancer. Besides traditional random or systematic approach, magnetic resonance imaging (MRI)-
guided technique has been recently introduced. 
Objective: To perform a systematic review of complications after transrectal ultrasound (TRUS)-
guided, transperineal and MRI-guided PB. 
Evidence Acquisition: We performed a systematic literature search of Web of Science, Embase and 
Scopus databases up to October 2015 according to the Preferred Reporting Items for Systematic 
Review and Meta-analysis (PRISMA) statement. Complications and mortality following random, 
systematic and image-guided PB were reviewed. Eighty-four references were included. 
Evidence Synthesis: The most frequent complication after PB is minor and self-limiting bleeding 
(hematuria and hematospermia), irrespective of the biopsy approach. Occurrence of rectal bleeding 
was comparable among traditional TRUS-guided and image-guided PB. Almost 25% of patients 
experience lower urinary tract symptoms, but only a few have urinary retention, with higher rates 
after transperineal approach. Temporary erectile dysfunction is not negligible, with a return to 
baseline after 1-6 months. The incidence of infective complications is being increasing, with higher 
rates among men with medical comorbidities and older age. Transperineal and in-bore MRI targeted 
biopsy may reduce the risk of severe infectious complications. Mortality after PB is uncommon, 
irrespective of biopsy technique. 
Conclusions: Complications after PB are frequent but often self-limiting. The incidence of 
hospitalization due to severe infections is continuously increasing. Still, a careful appraisal of 
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patient’s general health status, risk factors and likelihood of antimicrobial resistance should be done 
before scheduling a PB. 
Patient Summary: In this paper we reviewed the variety and incidence of complications after 
prostate biopsy. Even if frequent, seldom represent a problem for the patient. The most 
troublesome complications are infections. In order to minimize this risk, a careful evaluation of 
patient’s medical condition must be done before biopsy. 
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1. Introduction 
Prostate biopsy (PB), often guided by transrectal ultrasound (TRUS), is the gold standard 
technique to confirm the presence of cancer in men with suspicion for prostate malignancy.  
It is estimated that more than 2 million procedures are carried out in the United States and 
Europe every year1,2. Although prostate biopsy is often performed transrectally in an 
outpatient setting, they can also be performed via a transperineal approach, avoiding the 
rectum. Recently, magnetic resonance imaging (MRI) has been proposed in targeting 
biopsies towards suspicious areas, to improve the detection of clinically significant prostate 
cancer 3. The opportunity to perform a lesion-targeted biopsy  could reduce the number of 
biopsy cores taken and, therefore lower complications rates, without compromising 
detection rates. Our objective was to perform an updated systematic review of complication 
profiles after TRUS-guided systematic, transperineal and MRI-targeted prostate biopsy. 
  
2. Evidence Acquisition 
A PubMed search for English-language publications up to October 2015, with the search 
terms prostate biopsy AND complications was firstly performed. By this initial search 7000 
records were identified. Furthermore, 60 additional contributions were retrieved through 
hand and free-text search, including Web of Science, Embase and Scopus databases, by using 
the following search terms: fusion prostate biopsy AND complications; in bore prostate 
biopsy; prostate biopsy AND erectile dysfunction OR erectile function; image-guided prostate 
biopsy. All available reports containing data on complications after systematic, random and 
image-guided prostate biopsy were considered for eligibility.  Studies were finally included 
basing on the following criteria: (1) appropriate reporting of complications after PB, 
including, whenever available, the tools used to measure the adverse events; (2) randomized 
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controlled trials (RCTs) were firstly considered; (3) in the absence of RCTs, prospective cohort 
studies, series from national databases and retrospective studies were included; (4) in case 
of overlapping study design, only the report with the most comprehensive information or 
the largest population was included. Studies were excluded in case of: (1) editorials,  
abstracts or case reports; (2) absence of sufficient data on complications and rates of adverse 
events (3) publication date before 2002. The rate and type of complications after prostate 
biopsies was assessed and recorded for all contributions. The first Author (M.B.) screened all 
abstracts and full-text articles. A flowchart of the systematic search process is shown in 
Figure 1. Based on the above mentioned criteria, 85 unique references were ultimately 
included in this qualitative synthesis. 
 
3. Evidence Synthesis 
3.1 Bleeding Prostate biopsy is generally performed as a transrectal procedure in an outpatient 
setting, under local anesthesia, and is usually well-tolerated. Post-procedural bleeding, voiding 
dysfunctions and pain are common1, but are not clinically significant and seldom troublesome. 
Both patient-related (i.e. use of anticoagulant medications, coagulopathies, medical 
comorbidities, prostate volume, obstructive symptoms, and anxiety) and procedure-related (i.e. 
biopsy indication, technique, number of cores taken, and type of anesthesia) factors may impact 
on the occurrence of these complications.  
3.1.1 Hematuria 
Hematuria following prostate biopsy is common, with a reported  incidence of 2%- 84%1,4–
11, depending on the technical approach, definition, duration of follow-up and method of 
6 
 
data collection. Patient-related factors, such as prostate volume and medical comorbidities 
also influence the risk of hematuria. In a large prospective cohort of 1147 men undergoing 
TRUS-guided PB, hematuria was reported by 65.8% of patients within 35 days, but only 6.2% 
of them considered it bothersome7. In the European Randomized Study for Prostate Cancer 
(ERSPC), hematuria lasting more than 3 days occurred in 22.6% of cases, and was significantly 
correlated with higher prostate and transition zone volumes (p<0.001)11. The impact of the 
number of biopsy cores on hematuria is controversial, irrespective of the technique (TRUS-
guided or transperineal).  Ghani et al. found that the prevalence of hematuria did not vary 
with the number of TRUS-PB core (44% [6 cores], 41% [8 cores], 39% [12 cores])4, while 
others reported higher rates of bleeding with increased sampling12. Among 3000 patients 
undergoing transperineal biopsy, Pepe et al. reported hematuria in 10.4% of cases, 
regardless of the number of cores10. Higher rates of hematuria (73.4%) after transperineal 
PB were observed by others, although multivariate analysis did not reveal any predictive 
factors13. MRI-guided in-bore prostate biopsies have been associated with lower rates of 
overall complications compared to TRUS-guided PB, including bleeding. Egbers et al, in a 
prospective non-randomized study of 54 patients, recently reported hematuria in 51% of 
MRI-guided in-bore biopsy compared to 79% of transrectal PB (p=0.006), as well as a longer 
bleeding duration for the latter technique14. Moreover, a recent systematic review 
evaluating outcomes of MRI in-bore PB performed transrectally, transient hematuria 
occurred in 1%-24% of patients3. Hospital admissions rates for severe hematuria have been 
reported in <1% of cases1,2,15,16, and despite a higher average number of biopsy cores taken 
in recent years compared to historical data, the rate of bleeding complications has not 
changed over time. 
3.1.2 Rectal bleeding 
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Transrectal PB could lead to transient hematochezia, with reported rates of 1.3% - 45%1. As 
with hematuria, in the vast majority of men rectal bleeding is self-limiting and rarely 
bothersome. Indeed, in a large prospective study, rectal bleeding was common (36.8%), but 
only 2.5% of all patients found it a major or moderate problem according to the National 
Cancer Institute’s criteria7. Lower rates were reported within the ERSPC study (1.3%), with 
no correlation between hematochezia  and other clinical parameters11. Ghani et al. reported 
a significantly higher rates of rectal bleeding in men undergoing more biopsy cores (17% vs. 
26% vs. 27% after six, eight and 12-core biopsy, respectively)4. Berger et al reported an 
overall bleeding rate of 2.3%. In this TRUS-guided series, only 0.6% of patients experienced 
prolonged hematochezia or required surgical intervention for bleeding control, with no 
significant correlation with the number of cores taken5. The occurrence of hematochezia 
after MRI in-bore prostate biopsy ranged from 11% to 17%3, with no significant advantages 
offered by this approach over traditional TRUS-guided PB in terms of incidence and duration 
of bleeding in this population 14. Massive rectal bleeding is uncommon and management 
options include rectal balloon tamponade, endoscopic adrenaline injection or sclerotherapy, 
or direct endoscopic vessel clipping or ligation1. 
3.1.3 Hematospermia 
The presence of visible blood in the ejaculate is the most variably reported complication after 
prostate biopsy, ranging from 1.1%-92.6%1,5,7,11,13,17. Unlike hematuria or rectal bleeding, 
hematospermia could have a transient detrimental effect on sexual activity or trigger 
anxiety7,17.  In a large prospective cohort from the UK screening study, Rosario et al. reported 
hematospermia in 92.6% of patients within 35 days after PB, and 26.6% perceived it as a 
moderate/serious and bothersome problem7.  In the ERSPC study, hematospermia was 
reported in 50.4%, and was inversely correlated with age (p<0.001), previous transurethral 
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resection of the prostate (p<0.001) and prostate volume (p<0.001)11. Regardless of the 
procedural approach, the number of cores can influence incidence of hematospermia. In a 
retrospective study by Berger et al, hematospermia was the most frequently reported 
complication after TRUS-guided PB (36.3%), and was significantly higher with more cores 
taken (31.8%, 37.4% and 38.4% after 6-core, 10-core and 15-core biopsies, respectively; 
p<0.001). Similarly, Pepe et al. found that hematospermia significantly correlated with the 
number of cores following transperineal PB (30.4% and 10.7% following >/=24 cores vs. 12 
cores, respectively; p=0.001)10. Conversely, in a recent MRI in-bore PB series with a median 
of 4 cores, the rate of hematospermia was similar to TRUS-guided prostate biopsies with 10 
median cores (36% vs. 33%, p>0.05)14.  
3.1.4 Use of anticoagulants and bleeding complications  
A recent consensus-based recommendation from ICUD (International Consultation on 
Urological Disease)/AUA (American Urological Association) on anticoagulant and antiplatelet 
(AC/AP) therapy in urological practice18 stated that the risk of bleeding after PB in men using 
AC/AP must always be balanced against the hazard of cardiovascular or thromboembolic 
events when stopping such therapies, especially in high-risk patients (metal heart valves, 
drug eluting coronary stent, atrial fibrillation). Giannarini et al, randomly assigned 196 men 
undergoing TRUS-guided PB to continue low-dose aspirin, replace it with low molecular-
weight heparin or discontinue aspirin without replacement19. They found no significant 
difference in the overall bleeding rate (hematuria, rectal bleeding, and hematospermia) 
among the three groups (78.5%, 69.7%, and 81.5%, respectively; p = 0.26), and no severe 
bleeding occurred. However, the median duration of hematuria and rectal bleeding was 
significantly longer in men under AC/AP therapy than in those who stopped antiplatelet 
therapy (p<0.001)19. Comparable results have been reported by other authors20. Chowdhury 
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et al compared results of 930 men undergoing TRUS-guided PB with increasing sampling 
number (up to 10), without stopping warfarin or aspirin12. The type of bleeding complication, 
duration and severity significantly increased with an increasing number of cores in all 
patents. Interestingly, warfarin use, once controlled for core number and patient age, was 
not associated with bleeding events, duration or severity. Conversely, low-dose aspirin 
significantly increased the incidence of hematuria, and both incidence and duration of rectal 
bleeding. No severe hemorrhagic complications were reported12.  Similarly, Ihezue et al. 
reported no difference in incidence, duration or severity of bleeding in men using warfarin 
before TRUS-guided PB21. Accordingly, high-risk patients on low-dose aspirin or warfarin may 
have greater risk from AC/AP withdrawal than the risk of a serious bleeding complication.  
Consultation with the AP/AC prescribing physician can help balance risks and benefits of 
discontinuing AP/AC therapy to prevent biopsy related hemorrhage.   
3.2 Lower urinary symptoms and acute urinary retention 
A common side effect after transrectal PB is a short-term exacerbation of urinary symptoms, 
with reported rates of lower urinary tract symptoms (LUTS) from 6% -25% 1,13,22. The 
reported incidence of acute urinary retention after transrectal biopsy is substantially lower, 
ranging from 0.4% to 6% 1,9,11,23,24. Urinary retention is usually transient, and most patients 
do not require more invasive treatments than temporary placement of a urethral catheter. 
The exact pathophysiology of prostate biopsy-related voiding impairment is unclear, 
although it may be related to iatrogenic trauma from placing needles into the prostate, that 
could affect bladder outlet resistance and voiding symptoms. Prostate volume, in particular 
the transition zone volume, is a well-documented and significant factor associated with 
subjective voiding impairment and acute urinary retention in most studies22. For example, in 
5802 men from the Rotterdam section of the ERSPC, prostate volume, transition zone 
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volume/total prostate volume ratio, and a higher IPSS score were all predictors of urinary 
retention 11. Similarly, Aktas et al. found that patients with a prostate volume >38.8 mL  were 
more prone to voiding difficulty after transrectal ultrasound guided biopsy. The main 
limitations of this study are small sample size (92 men) and short follow-up (7 days) 24. Less 
data are available on urinary side effects of transperineal PB. Namekawa et al, recently 
reported on 2.086 men undergoing an initial PB under lumbar spinal anesthesia: PSA , IPSS 
score, prostate volume, abnormal DRE and history of α-blocker use were independent 
predictors of LUTS and urinary retention 13. When compared to TRUS-guided PB, the 
occurrence of acute urinary retention after transperineal approach is slightly higher, ranging 
from 1.7% to 11.1%8–10,25,26. Pepe et al. reported 11.1%, which was significantly correlated 
with the number of cores taken10,27. Tsivian et al showed a severe worsening of urinary 
symptoms with urinary retention in 6%, with a return to baseline within 6 weeks9. There are 
conflicting data on the association between number of cores and type of anesthesia with 
voiding symptoms after PB. Klein et al evaluated 198 patients randomized to undergo 
prostate biopsy with or without peri-prostatic nerve block (PPNB). Overall IPSS score was 
significantly increased in all at 1 week, which persisted at 1 and 3 months only in those men 
submitted to repeated saturation biopsy (p=0.007). Conversely, patients who underwent 10-
core prostate biopsy with PPNB had a higher IPSS score at 1 and 3 months compared to those 
without PPNB, but this was not statistically significant23. There are limited data on the impact 
of serial biopsies during active surveillance (AS) on voiding symptoms and risk of acute 
urinary retention, although limited evidence suggests no significant correlation between 
number of prostate biopsies and IPSS28. Based on the currently available data, the reported 
incidence of acute urinary retention after MRI-guided PB is sporadic, from 0% to 1%3,14,29.  
Voiding symptoms and risk of acute urinary retention after PB might be mitigated using 
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alpha-blockers, although results are conflicting. Chung et al. randomized 88 patients 
undergoing TRUS-guided PB to peri-procedural tamsulosin or no tamsulosin. Patients treated 
with Tamsulosin had better flow rates (p< 0.01) and lower postvoid residual urine volume 
(p< 0.05) than controls on postbiopsy days 1 and 7. No acute urinary retentions were found 
in those patients using Tamsulosin30. In summary, although almost 25% of patients 
experience transient LUTS, only a small proportion of these individuals experience urinary 
retention. The administration of alpha-blockers after PB could have a beneficial impact.  
 
3.3 Erectile dysfunction  
Prostate biopsies may lead to transient erectile dysfunction (ED), with complete recovery 
after 1-3 months28. Notably, currently available data are heterogeneous with respect to 
patient populations and ED classifications, and significant confounders could impair the 
reliability of results. Murray et al. showed 34% of patients with no ED at baseline had a 
decrease in IIEF score at 1 week; 20% and 24% continued to have lower scores at 1 and 3 
months, respectively. Age ≥60 years or above, the first biopsy setting and a diagnosis of PCa 
were the main predictors of IIEF score impairment at 1 and 3 months31. It has been 
hypothesized that extensive sampling during saturation PB could affect erectile function, but 
in multiple series the IIEF score impairment resolved within 6 months after biopsy, and no 
correlation was found between number of cores and IIEF scores28,32. Several anatomical 
hypotheses have been postulated, such as a compression on the neurovascular bundle by 
edema or hematoma, and neuropraxia caused by laterally directed biopsy needles. 
Moreover, the peri-prostatic nerve blockade (PPNB) could affect EF, due to the direction of 
anesthetic into the neurovascular bundles; however, the changes in IIEF seem to be similar 
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among the different analgesia techniques 22,23. Significant anxiety regarding the possibility of 
cancer may also have an impact on erectile function. One study found a reduction in all IIEF 
domains only among men diagnosed with prostate cancer on biopsy, while no significant 
decrease was found in their counterparts with negative biopsy results22.  With expanded use 
of active surveillance for clinically localized low risk PCa, many men with a diagnosis of 
prostate cancer are also undergoing repeated PB during follow-up. Considering the effect of 
serial TRUS-guided biopsy in 231 patients from an AS program, Fujita et al. demonstrated a 
significant correlation between number of biopsy sessions and decrease in EF. A history of 3 
or more biopsies was correlated to a greater EF impairment than 2 or fewer biopsies (p=0.02) 
28. Another prospective AS study of 342 patients undergoing TRUS-PB found that EF 
decreased by 1-point every year for the first 4 years 33. However, the impact of repeated PB 
itself on EF cannot be separated from the natural aging process and other potential 
confounders. In 427 men in an AS program, Hilton et al. showed that sexual activity level 
changed in >20% of respondents. However, no significant association between EF and 
increasing biopsy exposure was found after adjusting for age, sexual activity status, clinical 
stage and diagnostic period. 34 In summary, a non- negligible proportion of men undergoing 
biopsy experience ED; however they usually return to baseline EF by 1-6 month post-
procedure and it is unclear whether these changes are due to the biopsy itself versus 
psychological impact of the event or other confounders.  
3.4 Pain 
Although PB is well-tolerated in most of patients, techniques to reduce pain and discomfort 
are routinely employed in clinical practice. Different steps may cause pain during biopsy, 
such as probe insertion, periprostatic infiltration and biopsy sampling, extending up to 
several hours afterward. Previously reported predictors of pain include anorectal 
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compliance, younger age, prostate volume, number of biopsy cores, and lateral decubitus 
position that could may affect blood flow within the prostate 1. Anxiety is also an important 
factor that should be considered, especially in younger patients. Periprostatic nerve block 
(PPNB), which consists of injecting Lidocaine between the prostate base and seminal vesicle 
on each side (where the neurovascular bundles are anatomically positioned), is the most 
widely used anethetic for transrectal PB and has been shown to reduce pain compared to no 
anesthetic 1,35. However, PPNB does not alleviate the discomfort related to TRUS probe 
insertion and manipulation, and peri-prostatic anaesthetic infiltration itself is among the 
most painful parts of the procedure35. Consequently, non-infiltrative topical anaesthesia 
(e.g., creams, gels, and suppositories) represent potential alternatives to reduce discomfort. 
Lidocaine gel was among the first and most used local anaesthetic agents due to its low cost 
and safety. Reports showed significantly less pain with probe insertion and manipulation 
compared to placebo36, but it did not reduce pain related to  anaesthetic infiltration and 
needle biopsy. A combination of 2.5% lidocaine and 2.5% prilocaine (EMLA© cream) was 
found to be superior to other topical anaesthetic agents, possibly due to its longer duration 
(2–5 hours) and deeper tissue infiltration37. Furthermore, suppositories based on non-
steroidal anti-inflammatories (e.g., diclofenac) can be used to reduce the local and 
systematic anti-inflammatory effect, but do not significantly reduce pain from probe 
manipulation and biopsy sampling38. Comparing lidocaine gel with lidocaine-ketorolac and 
lidocaine-prilocaine cream, the latter was the most effective on probe-related pain, whereas 
lidocaine-ketorolac gel was most useful for sampling-related pain39. Another alternative 
form of anesthesia is pelvic plexus block (administration of lidocaine in the area of the pelvic 
plexus, lateral to the tip of seminal vesicles on each side)40 and a combination of intra-
capsular anesthesia and PPNB41, which was found to provide superior analgesia to PPNB 
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alone. Interestingly, Iremashvili et al reported that patients receiving combined PPNB and 
bilateral pudendal block during transperineal PB had significantly better pain control 
throughout the probe insertion, biopsy sampling, and at 1 hour post-procedure, compared 
to PPNB alone42. There is also increasing interest in combining topical and infiltrating 
anaesthesia. As consequence, Raber at al. showed that a combination of intra-rectal local 
analgesia using a lidocaine-prilocaine cream and PPNB was superior to PPNB alone in 
controlling pain during TRUS-guided PB and may have maximum benefit for younger 
patients43.  Similarly, Giannarini et al. found that the combination of perianal-intrarectal 
lidocaine-prilocaine cream and PPNB was able to provide better pain control than the two 
modalities alone, with no increase in the complication rate. The magnitude of this effect was 
higher in younger men, especially if with an enlarged prostate and lower anorectal 
compliance44 .A recent meta-analysis confirmed that the combination of local analgesia and 
PPNB significantly reduced pain associated with probe manipulation, anesthesia, infiltration 
and needle biopsy. Subgroup analyses suggest that lidocaine-prilocaine cream proved the 
most effective pain control regardless of the origin of pain38. Moreover, Cormio et al 
compared the efficacy of topical anesthesia (combined lidocaine-prilocaine cream with 
lidocaine-ketorolac gel) with the combination of topical and infiltrating anesthesia 
(lidocaine-prilocaine cream plus PPNB): both anaesthetic regimens provided almost 
comparable pain at probe insertion, movement and during sampling, but patients receiving 
the second regimen reported significantly greater maximal procedural pain scores (p<0.001).  
With MRI in-bore PB, some patients now undergo prostate sampling limited to suspicious 
lesions, resulting in significantly less pain intensity and duration compared to the traditional 
transrectal procedure. In the study by Egbers et al, pain intensity was significantly lower for 
MRI-in bore PB compared with TRUS-PB (P = 0.005), and, similarly, pain duration was shorter 
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after the former technique 14. Table 1 summarizes the outcomes of the most relevant 
randomized trials evaluating pain during and after PB. In conclusion, optimal pain control is 
essential in order to reduce discomfort and improve patients’ acceptance of biopsy. 
Although the best clinical practice consists of combined local analgesia with PPNB, proper 
patient selection for  higher level analgesia is crucial in order to achieve individualized pain 
control. 
3.5 Infectious complications and hospitalization rates after prostate biopsy  
Infections are well-established adverse events after TRUS-guided PB. Asymptomatic bacteriuria, 
febrile urinary tract infections (UTI), acute bacterial prostatitis, orchitis, epididymitis, and urinary 
sepsis represent the broad spectrum of possible infectious complications 1,45,46. Accordingly, 
antibiotic prophylaxis is recommended as the standard of care 1,47,48. Fluoroquinolones were the 
drug of choice since the introduction of PB because they achieve high concentrations in the 
prostatic tissue and have broad-spectrum activity against common urogenital pathogens. 
However, growing fluoroquinolone-resistance has recently led to increasing rates of infective 
complications.  Fluoroquinolone resistant organisms have been identified in 10-30% of patients 
undergoing rectal swab culture before PB 47,49–52, although rates of clinical infectious 
complications are lower at approximately 1- 17.5%7,45,46,48,53–57. Most infections are self-limiting 
and can be managed in the outpatient setting 7,45. However, the incidence of more serious 
infectious complications requiring hospitalization has dramatically increased over time 2,15,58–60, 
with fluoroquinolone-resistant (FQR) Escherichia Coli as the most recognized risk factor 2,45,47,49–
51,53. In this scenario, patients with biopsy-related bacterial acute prostatitis have a higher risk 
of sepsis when compared to those with spontaneous acute prostatitis, probably due to a 
different pathogenic bacterial strain among the two groups61. Furthermore, medical 
comorbidities (particularly diabetes or metabolic syndrome) and older age are independent 
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predictors increasing the risk of infections and sepsis 45,58,60,62. A previous history of prostatitis,  
antibiotics within 6 months before PB, and non- adherence to antibiotic prophylaxis represent 
other risk factors46. Whether a repeated biopsy protocol, including those done in active 
surveillance (AS), could increase the risk of infection is unclear.  In a recent study by Ehdaie et 
al, the risk of infection significantly increased for each additional previous biopsy (OR: 1.33; 95% 
CI: 1.01-1.74, p=0.04), up to a rate of 15% for patients who had undergone ≥5 biopsies 6. 
Similarly, Loeb et al, reported a cumulative increase in the risk of having a complication where 
each additional biopsy was associated with a 1.7-fold increase in overall hospitalizations, and a 
1.7-fold increase in serious infectious complications. However, in a biopsy-based multivariable 
analysis, the repeat biopsy procedure itself was not associated with a greater risk of serious 
complications requiring hospital admission compared to the initial biopsy session 59. In patients 
undergoing transperineal PB, the reported incidence of infections and sepsis is close to zero (0-
0.2%), given the avoidance of bacterial contamination (which is common during transrectal 
access), as well as the limited number of cores taken when performing transperineal MRI-guided 
in bore biopsy 8–10,13,25–27,29,63–67. Although data are currently limited, it is uncertain whether the 
lower incidence of infectious complications after MRI-targeted PB could be related to the 
sampling route (i.e. transperineal) or the low number of cores taken. In a comparative series of 
patients undergoing transrectal MRI-targeted PB and TRUS-guided PB, the Authors found a 
lower incidence of infective complications in the former group (the rate of infections was halved 
compared to the latter), even if not statistically significant14. Conversely, the infectious 
complication rate after in-bore transperineal MRI-targeted biopsy appears virtually absent, with 
a hospitalization rate of 0% 29,64.A minority of patients require hospitalization for the 
management of serious biopsy-related adverse events or the exacerbation of underlying medical 
conditions. Data on hospital admissions following PB were recently reported by Anastadiasis et 
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al. from the English national cancer registry 58. Of the 198,361 men who underwent PB between 
2000 and 2008, 3.7% required hospitalization because of biopsy-related complications 
(UTI/sepsis, haematuria and urinary retention in 1.1%, 1.4% and 1.3% of men, respectively). 
Independent predictors of complications requiring hospitalization were age and comorbidities, 
with a roughly fourfold increased risk of admission at age ≥ 85 years compared to ages 45-54, 
and more than threefold increased risk in those men with two or more comorbidities. 
Remarkably, the hospitalization increased during the study period (20% greater incidence, 
p=0.03), predominantly due to urinary tract infections or sepsis (70% higher incidence in 2008 
than in 2000), while rates of hematuria and urinary retention remained stable 58. Nam et al was 
the first to report rising rates of hospitalization over time in a retrospective analysis of 75,190 
biopsied men from Canada. They reported an overall hospitalization rate of 1.4% within 30 days 
from TRUS-guided PB, with an increasing occurrence from 1996 to 2005 for both prostate 
cancer-positive and negative patients. Infections dramatically increased over time (from 0.6% in 
1996 to 3.6% in 2005), with no significant differences based upon age. Those men undergoing 
systematic repeated biopsy experienced a similar complication rate compared to those 
undergoing initial biopsy 15. In a study from the SEER database, Loeb et al. reported a 6.9% 30-
day overall hospitalization rate after PB. More medical comorbidities, non-white race and later 
year were significant risk factors 2. A Canadian, retrospective study of 5798 PB patients reported 
a hospitalization rate of 0.5%, all due to infection. Independent predictors were a more recent 
year of biopsy (OR: 4.74, p<0.001), diabetes (OR: 4.78, p=0.01), chronic obstructive pulmonary 
disease (OR: 5.66, p=0.005) and a history of recent hospitalization (OR: 8.83, p=0.03) 60. In men 
from the Rotterdam section of the ERSPC, the hospitalization rate within 14 days after biopsy 
was 0.8%, primarily due to infection (81%). Similar to previously reported studies, year of biopsy 
was an independent predictor of hospital admissions, with a 10% increase over time, likely 
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related to the rising FQR. Fluoroquinolones, indeed, have been widely used as prophylaxis for 
TRUS-guided PB and for the treatment of urological infections for the last two decades but the 
number of FQR bacteria have been increased over time 47,49,53. Other relevant studies 
7,11,16,48,49,59,68–70 reporting a similar hospitalization rate are summarized in Table 2. A recent 
statewide study from the Michigan Urological Surgery Improvement Collaborative (MUSIC) 
group, reported a reduction in hospitalization rates for infectious complications from 1.19% to 
0.56%, when adopting a specific protocol for antibiotic prophylaxis (by shifting from a mono-
therapy to a multi-drug prophylaxis or performing culture-directed prophylaxis) 51. Although 
transperineal approach for PB is infrequently used in many parts of the world largely due to 
logistical reasons, the  incidence of re-admissions for urinary infection or sepsis is lower, ranging 
from 0% to 0.7% in published reports 9,10,25,26(Table 2).Despite the currently limited available 
body of literature, the lower incidence of infections and hospitalizations among patients 
undergoing MRI-targeted PB appears mostly related to the transperineal access, rather than the 
number of cores taken  29,64. In summary, the occurrence of serious major complications after 
transrectal PB requiring hospital admission, ranges from 0.5% to 6.9%, and has increased over 
time. In the absence of grade I evidences, based on the currently available data, transperineal 
and limited sampling with in-bore MRI targeted biopsy seems to be associated with a reduced 
risk of severe infectious complications.  
3.6 Biopsy protocol modification to reduce the risk of infectious complications  
Several strategies have been proposed to reduce the risk of infectious complications in men 
undergoing PB1. Pre-biopsy rectal enemas, either with glycerin/saline or povidone-iodine (PI), 
are one first-line option. Kam et al. reported a significantly lower rate of complications by 
administering  glycerin/saline enema one hour before TRUS-guided PB (4.7% vs. 8.9%, 
p=0.007)71. Abughosh and collaborators reported fewer infections in men randomized to PI 
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cleansing compared to no cleanse, although it was not statistically significant (2.6% vs. 4.5%, 
p=0.15)56. A recent systematic review and meta-analysis showed that rectal PI enemas 
significantly reduced the risk of fever, bacteriuria and bacteremia compared to no cleansing 
(Risk Ratio: 0.3; 95% CI 0.21-0.45), while the combination of PI enemas and antibiotics was 
superior in reducing fever and bacteremia versus antibiotics alone in men undergoing 
transrectal PB (Risk Ratio: 0.23; 95% CI: 0.10-0.54)72. Even though short-term ciprofloxacin 
prophylaxis may still be adequate in a non-FQR population54,73, antibiotic prophylaxis 
augmentation or switching have been proposed by many studies to prevent severe infectious 
complications. Adibi et al. showed that the addition of 1 dose of intramuscular gentamicin 
before transrectal PB to the standard ciprofloxacin or trimethoprim/sulfometoxazole 
significantly reduced infection rates (0.6% vs 3.8%, p<0.001) and costs related to 
hospitalization74. Similarly, adding intramuscular amikacin75, gentamicin76, ceftriaxone68 or 
amoxicillin-clavulanate77 to fluoroquinolones have been shown to reduce infectious 
complications after TRUS-guided PB. Others have reported favorable results by switching from 
ciprofloxacin 500 mg plus aminoglycosides to levofloxacin 750 mg plus aminoglycosides78, by 
mixing 1 gram of ceftriaxone into the periprostatic lidocaine injection79 or by combining 
intramuscular cephalosporin with povidone-iodine suppositories57. A growing body of non-
randomized studies support rectal swab-targeted prophylaxis for transrectal PB. Duplessis et al. 
showed no infectious complications in men receiving targeted prophylaxis, in contrast with 
those using standard ciprofloxacin80. Similarly, Cook and collaborators reported a significant 
drop in infections after the introduction of rectal swab-targeted prophylaxis in routine clinical 
practice compared to a retrospective cohort receiving standard fluoroquinolones(0.41% vs. 
2.65%, p<0.05)81. Dai et al. recently reported clinically fewer infections (1.9% vs. 2.9%) in men 
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managed with targeted antibiotic prophylaxis, although the difference was not statistically 
significant (p=0.53)82.   
3.7 Mortality following prostate biopsy 
Despite the rates of minor and major complications, mortality after PB is uncommon. As 
previously reported, bleeding and infections represent the two most frequent adverse events 
which may be severe enough to require hospitalization, but rarely lead to death. To date, most 
PB-related deaths are due to septicemia and septic shock. Gallina and co-workers reported a 
large population-based study evaluating the mortality in men undergoing PB between 1989- 
2000 in Canada. 83. A higher overall 120-day mortality rate was observed in the 22,175 patients 
who underwent biopsy compared to the 1778 controls (1.3% vs. 0.3%, respectively, p<0.001). 
Increasing age and comorbidity were independent predictors of mortality on multivariable 
analysis, but interestingly the rate of fatal events was found to be higher in patients subjected 
to only one PB (1.4%), compared to those with 3 or more biopsies (0.6%). Contrasting results 
have been reported by two other large reports from the ERSPC 84 and PLCO 85 screening trials. 
Screen-positive patients undergoing PB experienced a similar 120-day mortality rate compared 
to screen-negative patients in the ERSPC (0.24% vs. 0.24%, p=0.96). 84 In the PLCO, a lower rate 
of deaths after 120 days, albeit not significant, was observed in men who had undergone PB 
compared to controls (0.095% vs. 0.18%, respectively) 85. It must be noted that, in both studies, 
almost all reported deaths were related to the deterioration of underlying chronic medical 
conditions (e.g. ischemic heart disease, pancreatitis, cancer, pneumonia). Thus, the use of 120-
day mortality rates may over-estimate mortality rates from PB since other competing causes 
may confound the results. Indeed, Nam et al reported a 30-day mortality rate of 0.09% among 
the non-cancer group who had a PB – the healthiest screened group of men15. Also, a low 30-
day mortality rate was reported in men undergoing PB compared to controls (0.31% vs. 1.09%) 
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in a US report from the SEER-Medicare database by Loeb et al, after adjusting for age, race, 
region, year and comorbidity (OR: 0.29; 95% CI, 0.22-0.38; p<0.001). However, men who were 
hospitalized for infectious complications had a 12-fold higher 30-day mortality rate in 
comparison to those who were not (95% CI 8.59 –16.80, p<0.0001) 2. Similar results were 
reported in a recent Swedish nationwide population-based study, with a 90-day mortality rate 
of 1%, and a significantly higher odds of dying for hospitalized patients than those not admitted 
to the hospital (OR: 12.6; 95% CI: 2.4-61.8, p=0.002) 45. Repeat biopsy is not associated with a 
higher overall mortality rate59.  Based on the currently available evidence, fatal events after 
prostate biopsy are uncommon, and the risk has remained relatively stable over time. Older age, 
the deterioration of underlying medical conditions and severe septic events represent the most 
important risk factors for death after biopsy.  
4. Conclusions 
The most frequently reported complication after PB is minor and self-limiting bleeding, 
irrespective of the biopsy approach or technique. Some men also experience transient lower 
urinary symptoms or erectile dysfunction. While less common, acute urinary retention does 
occur particularly after transperineal biopsy in patients with an enlarged prostate or with more 
biopsy cores. Optimal pain control, either by topical or infiltrative anaesthesia, reduces 
discomfort and improves biopsy acceptance. When compared to transrectal or transperineal 
systematic PB, MRI-guided biopsies have shown to reduce the rate of lower urinary symptoms 
and pain. Hospital admissions after PB have increased over time, mainly because of infectious 
complications. Older age, pre-existing comorbidities and the development of antimicrobial 
resistance represent the most important risk factors for infection after biopsy. Despite the 
paucity of data and the absence of comparative studies, the incidence of serious infections, 
sepsis or hospitalizations after MRI-guided PB is marginal. Mortality after PB is uncommon. 
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Overall, a careful appraisal of patient’s general health status and risk factors for antimicrobial 
resistance should be done before scheduling a prostate biopsy. 
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